Arginine as an Adjuvant Treatment Against Tuberculosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130305101446im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this study was to investigate if adjuvant treatment with arginine (the substrate for nitric oxide production) rich food supplements could improve clinical outcome in patients with smear positive tuberculosis by affecting nitric oxide production.
Condition | Intervention |
---|---|
Tuberculosis HIV |
Dietary Supplement: Peanuts Dietary Supplement: Daboqolo |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Supportive Care |
Official Title: | Arginine Rich Food Supplementation as an Adjuvant Treatment Against Tuberculosis |
- Final outcome according to WHO [ Time Frame: 8 months ] [ Designated as safety issue: No ]
- Change in Chest X-ray pattern from baseline to 2 months [ Time Frame: 2 months ] [ Designated as safety issue: No ]
- Levels of exhaled and urinary nitric oxide [ Time Frame: First week, week 2, week 8, and month 5 ] [ Designated as safety issue: No ]
- Weight gain from baseline until 2 months [ Time Frame: 2 months ] [ Designated as safety issue: No ]
- Sedimentation rate [ Time Frame: 2 months ] [ Designated as safety issue: No ]
- Sputum smear conversion [ Time Frame: 2 months ] [ Designated as safety issue: No ]
- Reduction of cough from baseline to 2 months [ Time Frame: 1 and 2 months ] [ Designated as safety issue: No ]
Enrollment: | 180 |
Study Start Date: | February 2004 |
Study Completion Date: | December 2006 |
Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: Peanuts |
Dietary Supplement: Peanuts
30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
|
Active Comparator: Daboqolo |
Dietary Supplement: Daboqolo
30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
|
Detailed Description:
Tuberculosis (TB) is disease of increased global public health importance. Because of emerging multi drug resistance and the long treatment duration there is a need to optimize the current chemotherapy. Host immunity is important in determining the susceptibility and outcome of disease as could be exemplified by co infection with HIV which dramatically increases the risk to develop TB.
Previous results from our group and others show that nitric oxide produced by activated macrophages from arginine might be important to control the disease. However, the relative importance of nitric oxide in human TB has been debated. In a previous study in Gondar, Ethiopia, we observed an effect of adjuvant treatment with arginine capsules on sputum smear conversion and reduction of cough. In this study we wanted to test the hypothesis based on previous observations that an arginine rich food supplementation might enhance clinical improvement in patients with smear positive tuberculosis and if this effect could be due to increased nitric oxide production.
![](https://webarchive.library.unt.edu/web/20130305101446im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 15 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Informed and written consent to take part in the study
- Previously untreated and newly diagnosed smear positive Tb patients according to the WHO definitions
Exclusion Criteria:
- Hospitalization
- Pregnancy
- Known allergy against peanuts
- Chronic or acute disease other than tuberculosis/HIV
![](https://webarchive.library.unt.edu/web/20130305101446im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ethiopia | |
Gondar University, DOTS-center | |
Gondar, Region 3, Ethiopia, Gondar, Ethiopia, P.o. box 106 |
Principal Investigator: | Thomas Schön, MD PhD | Linkoeping University |
Study Director: | Sven Britton, Professor | Karolinska Institutet |
Study Chair: | Tommy Sundqvist, Professor | Linkoeping University, Sweden |
![](https://webarchive.library.unt.edu/web/20130305101446im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Thomas Schön, Linkoeping University |
ClinicalTrials.gov Identifier: | NCT00857402 History of Changes |
Other Study ID Numbers: | ArgII, HLF_20060246 |
Study First Received: | March 5, 2009 |
Last Updated: | March 5, 2009 |
Health Authority: | Ethiopia: Ethiopia Science and Technology Commission Sweden: Regional Ethical Review Board |
Keywords provided by Linkoeping University:
Arginine Nitric oxide Peanuts Sedimentation rate |
Additional relevant MeSH terms:
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on March 03, 2013